Schrödinger, Inc.

NASDAQ:SDGR

Medical - Healthcare Information Services

Healthcare
$27.20 +0.01%

+$0.00 today

Market cap
$1.79B
Beta
1.64
P/E (TTM)
-11.1
EPS (TTM)
-$1.40
52W Low $10.95High $23.75

Volume 1.18M

Average 1.35M

SDGR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Schrödinger, Inc.NASDAQ: SDGR

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development declines year over year

Q3 FY2026 research & development of $34.09M fell 20.3% year over year, behind the -11.5% change in trailing-twelve-month research & development. Sequentially, it fell 16.8% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.

Context

  • Research & development amounted to 67.7% of revenue in FY2025, down 29.6 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -20.3% toward the trailing-twelve-month pace of -11.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$34.09M-16.8% QoQ
Last fiscal yearDec 2025
$173.14M-14.2% YoY
LTMSep 2026
$160.31M-11.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.3%——
1 year-14.2%——
3-year CAGR+11.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
173.14M USD
Year-over-year change
-14.2%
4-year CAGR
+17.5%

Research & Development vs competitors

How SDGR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.5% is the 8th highest of 9, against a peer median of +7.2%.
  • Research & development amounts to 59.6% of revenue for SDGR, versus a peer median of 24.8%.
SDGR Competitors
Research & Development for SDGR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VEEVVeeva Systems Inc.LTM Jul 2026$821.92M USD+12.5%+13.8%23.8%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$270.72M USD-4.1%+2.0%2615.7%
GENBGenerate Biomedicines, Inc.FY2025$224.7M USD+28.2%—704.5%
ABCLAbCellera Biologics Inc.LTM Sep 2026$186.28M USD+1.9%+20.1%274.5%
SDGRSchrödinger, Inc.LTM Sep 2026$160.31M USD-11.5%+11.1%59.6%
CERTCertara, Inc.LTM Mar 2026$42.8M USD+20.1%+13.3%10.2%
LTRNLantern Pharma Inc.LTM Mar 2026$9.98M USD-34.1%+10.2%—
SLPSimulations Plus, Inc.LTM Feb 2026$9.34M USD+29.5%+29.0%11.6%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$4.56M CAD+1.7%-13.6%24.8%
Peer median (excluding SDGR) —+7.2%+13.3%24.8%

Competitors are the stored peer set for SDGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue137.93M180.96M216.67M207.54M255.87M
Cost of Revenue72.31M79.93M75.97M75.46M113.26M
Gross Profit65.62M101.02M140.69M132.08M142.61M
Gross Margin47.6%55.8%64.9%63.6%55.7%
Research & Development90.9M126.37M181.77M201.79M173.14M
Selling, General & Admin86.16M121.47M136.37M139.59M136.37M
Operating Expenses177.06M247.84M318.14M341.38M309.51M
Depreciation & Amortization2.85M4.34M5.55M6.16M6.02M
EBITDA(97.96M)(144.78M)48.47M(179.55M)(96.3M)
EBITDA Margin-71.0%-80.0%22.4%-86.5%-37.6%
Operating Income(111.44M)(146.82M)(177.45M)(209.3M)(166.9M)
Operating Margin-80.8%-81.1%-81.9%-100.8%-65.2%
Interest Income1.06M3.95M000
Interest Expense03K000
Other Income / Expenses10.64M(2.31M)220.37M23.59M64.57M
Income Before Tax(100.81M)(149.12M)42.92M(185.71M)(102.33M)
Pre-Tax Margin-73.1%-82.4%19.8%-89.5%-40.0%
Income Tax Expense411K63K2.2M1.41M939K
Net Income(100.39M)(149.19M)40.72M(187.12M)(103.27M)
Net Margin-72.8%-82.4%18.8%-90.2%-40.4%
EPS (Basic)(1.43)(2.10)0.57(2.57)(1.41)
EPS (Diluted)(1.43)(2.10)0.54(2.57)(1.41)
Weighted Avg Shares70.59M71.17M71.78M72.67M73.44M
Weighted Avg Shares (Diluted)70.59M71.17M74.99M72.67M73.44M

Schrödinger, Inc.

NASDAQ:SDGR

Intrinsic Alpha fair value

Locked

Current Price

$27.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.